Share on StockTwits

Sangamo Biosciences (NASDAQ:SGMO) CFO Henry Ward Wolff sold 15,000 shares of the company’s stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $13.26, for a total value of $198,900.00. Following the transaction, the chief financial officer now directly owns 220,347 shares in the company, valued at approximately $2,921,801. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Sangamo Biosciences (NASDAQ:SGMO) traded up 1.47% during mid-day trading on Friday, hitting $13.76. The stock had a trading volume of 352,005 shares. Sangamo Biosciences has a 1-year low of $8.93 and a 1-year high of $24.69. The stock has a 50-day moving average of $14.86 and a 200-day moving average of $16.57. The company’s market cap is $935.1 million.

Sangamo Biosciences (NASDAQ:SGMO) last released its earnings data on Tuesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. The company had revenue of $8.10 million for the quarter, compared to the consensus estimate of $6.59 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. The company’s revenue for the quarter was up 76.1% on a year-over-year basis. Analysts expect that Sangamo Biosciences will post $-0.29 EPS for the current fiscal year.

Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.